- Conditions
- Gastric Cancer
- Interventions
- Rilotumumab, Placebo, Epirubicin, Cisplatin, Capecitabine
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 609 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Aurora, Colorado • Pueblo, Colorado + 13 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–288
of 324
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neoplasms, Gastrointestinal Tract
- Interventions
- Lapatinib, Placebo, Capecitabine, Oxaliplatin
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 545 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2024
- U.S. locations
- 10
- States / cities
- Alhambra, California • Fullerton, California • La Verne, California + 7 more
- Conditions
- Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC)
- Interventions
- AB598, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Lake City, Florida + 8 more
- Conditions
- Esophageal Cancer, Gastric Cancer
- Interventions
- filgrastim, cisplatin, fluorouracil, paclitaxel, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 66
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Duarte, California + 54 more
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Interventions
- Elironrasib, Daraxonrasib
- Drug
- Lead sponsor
- Revolution Medicines, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 534 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 23
- States / cities
- Duarte, California • Orange, California • Sacramento, California + 17 more
- Conditions
- Esophageal Cancer, Gastric Cancer
- Interventions
- exatecan mesylate
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 5
- States / cities
- Long Beach, California • Denver, Colorado • Dallas, Texas + 2 more
- Conditions
- Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Glioblastoma Multiforme, Cholangiocarcinoma, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Epithelial Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Soft Tissue Sarcoma, Gastric Adenocarcinoma, Malignant Mesothelioma (MM), Von Hippel Lindau, Bladder Cancer, Bladder Urothelial Carcinoma
- Interventions
- 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors
- Diagnostic Test
- Lead sponsor
- Telix Pharmaceuticals (Innovations) Pty Ltd
- Industry
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Miami, Florida • Boston, Massachusetts + 7 more
- Conditions
- Solid Tumor
- Interventions
- ACTM-838
- Drug
- Lead sponsor
- Actym Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Pittsburgh, Pennsylvania
- Conditions
- Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Ovarian Epithelial Cancer, Carcinoma Breast Stage IV, Hormone-refractory Prostate Cancer, Head and Neck Cancers- Squamous Cell, Renal Cell Cancer, Urinary Bladder Neoplasms, Cervical Cancer, Endometrial Cancer, Glioblastoma Multiforme, Triple Negative Breast Cancer, Pancreatic Cancer
- Interventions
- Sacituzumab Govitecan-hziy (SG)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 515 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 12
- States / cities
- Aurora, Colorado • New Haven, Connecticut • Newark, Delaware + 8 more
- Conditions
- Esophageal Neoplasms, Adenocarcinoma of the Gastroesophageal Junction, Gastroesophageal Cancer, Squamous Cell Carcinoma, Gastric Adenocarcinoma
- Interventions
- DKN-01 150 mg, Paclitaxel, Pembrolizumab, DKN-01 300 mg
- Drug
- Lead sponsor
- Leap Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 10
- States / cities
- Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 5 more
- Conditions
- Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Esophageal Carcinoma, Fallopian Tube Carcinoma, Gastric Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Invasive Breast Carcinoma, Lung Non-Small Cell Carcinoma, Lung Small Cell Carcinoma, Malignant Solid Neoplasm, Melanoma, Metastatic Prostate Carcinoma, Multiple Myeloma, Ovarian Carcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Carcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Triple-Negative Breast Carcinoma
- Interventions
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Medical Chart Review, Paracentesis, Positron Emission Tomography
- Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 1,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 147
- States / cities
- Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 115 more
- Conditions
- Colorectal Cancer, Gastro Esophageal Junctional Cancer, Gastric Cancer (GC), GEJ Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC), Gall Bladder Cancer, Cholangiocarcinoma
- Interventions
- IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody
- Drug
- Lead sponsor
- Iksuda Therapeutics Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Boston, Massachusetts • Nashville, Tennessee + 1 more
- Conditions
- Gastric Neoplasms, Esophageal Cancer, Liver Cancer, Liver Metastasis, MSS-CRC, MSS, Gastric Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Metastases, MSI-H, Gastric Cancer
- Interventions
- vvDD-hIL-2-RG-1
- Biological
- Lead sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
- Other
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer, Invasive Breast Carcinoma, Cutaneous Melanoma, Esophageal Carcinoma, Gastroesophageal Junction Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck, Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Endometrial Carcinoma, Renal Cell Carcinoma, Rectal Adenocarcinoma, Colon Adenocarcinoma
- Interventions
- Guardant Reveal
- Diagnostic Test
- Lead sponsor
- Guardant Health, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Hot Springs, Arkansas + 30 more
- Conditions
- Epithelial Ovarian Cancer, Gastro-esophageal Junction Cancer, Soft Tissue Sarcoma (STS), Myxoid Liposarcoma, Synovial Sarcoma
- Interventions
- Lymphodepletion, TCR-T cells (MDG1015)
- Drug · Biological
- Lead sponsor
- Medigene AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2042
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Esophageal Cancer, Gastric Cancer
- Interventions
- Bevacizumab, Docetaxel, Oxaliplatin
- Biological · Drug
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2013
- U.S. locations
- 4
- States / cities
- Ann Arbor, Michigan • Detroit, Michigan • Columbus, Ohio
- Conditions
- Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Pancreatic Cancer, Biliary Tract Cancer, Cholangiocarcinoma, Metastatic Cancer
- Interventions
- BNT141, Nab-paclitaxel, Gemcitabine
- Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 4
- States / cities
- Duarte, California • Houston, Texas • San Antonio, Texas
- Conditions
- Esophageal Cancer, Gastric Cancer
- Interventions
- aminocamptothecin
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2003
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • Decatur, Illinois • Peoria, Illinois + 3 more
- Conditions
- Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer, Pancreatic Cancer
- Interventions
- LB1908
- Biological
- Lead sponsor
- Legend Biotech USA Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 9
- States / cities
- Tampa, Florida • Detroit, Michigan • Hackensack, New Jersey + 6 more
- Conditions
- Muscle Invasive Bladder Urothelial Carcinoma, Esophageal Cancer, Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Melanoma (Skin Cancer), NSCLC (Non-small Cell Lung Cancer), Pancreatic (Exocrine Only), Mix of Solid Tumors (MOST)
- Interventions
- blood and tissue samples, blood and tissue samples
- Diagnostic Test · Other
- Lead sponsor
- Paradigm Health
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Bullhead City, Arizona • Casa Grande, Arizona + 43 more
- Conditions
- Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Stage III Esophageal Cancer AJCC v7, Stage III Gastric Cancer AJCC v7, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7, Unresectable Esophageal Carcinoma, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
- Interventions
- Olaparib, Ramucirumab
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 32
- States / cities
- Corona, California • Duarte, California • Lancaster, California + 24 more
- Conditions
- KRAS G12D Mutation, Advanced Solid Cancer
- Interventions
- ARV-806
- Drug
- Lead sponsor
- Arvinas Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • New Haven, Connecticut • Tampa, Florida + 9 more
- Conditions
- Progressive Metastatic Malignancies
- Interventions
- ALT-801
- Biological
- Lead sponsor
- Altor BioScience
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Orlando, Florida • Tampa, Florida + 1 more
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
- Interventions
- telephone-based intervention, nicotine replacement therapy, informational intervention, internet-based intervention, questionnaire administration
- Behavioral · Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Buffalo, New York